Dow closes 200 points lower for worst day in May as Fed reignites inflation worries: Live updates
The major averages declined Wednesday after the latest Fed meeting minutes indicated the central bank is apprehensive about when to cut rates.
Morgan Stanley’s Slimmon names tech stocks to buy at a ‘reasonable price’
Though he fears a change in market conditions could cause “some sort of equity correction,” the portfolio manager says it’s “clear sailing” for stocks for now.
When Nvidia beats estimates, these 6 AI stocks tend to rise
Five U.S.-listed stocks and one Japan-listed company have risen between 6% and 33% after Nvidia revealed bumper earnings in the past.
‘Big Short’ investor Steve Eisman: Apple is the ‘hidden AI play’
Investor Steve Eisman of “The Big Short” fame expects Apple to capture epic gains from the artificial intelligence boom.
Uniswap urges SEC to drop potential enforcement action in new filing: CNBC Crypto World
CNBC Crypto World features the latest news and daily trading updates from the digital currency markets and provides viewers with a look at what’s ahead with high-profile interviews, explainers, and unique stories from the ever-changing crypto industry….
Biden to release 1 million barrels of gasoline to reduce prices at the pump ahead of July 4
The Biden administration will release 1 million barrels of gasoline from reserves held in the Northeast to reduce prices ahead of the July 4 holiday.
Uniswap fights back against SEC as the ethereum crackdown continues
Uniswap fights back against SEC Wells notice.
UBS says it’s time to move out of cash. Here’s where it sees opportunity
While investors have been earning yield of more than 5% on money market funds and CDs, those rates aren’t expected to stick around much longer.
World Economic Forum founder Klaus Schwab to step back from executive role
The World Economic Forum confirmed that founder Klaus Schwab is moving away from the day-to-day management of the organization after more than 50 years at the helm.
JPMorgan says there’s a new GLP-1 drug player and its shares can rally 80%
Structure Therapeutics could one day boast a competitive obesity product and go up against Eli Lilly and the like, according to JPMorgan.
